Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 94Neoplasm Metastasis 9Prostatic Neoplasms, Castration-Resistant 5Breast Neoplasms 3Neoplasms 2Metastatic Castration Resistant Prostate Cancer 2Castration-resistant Prostate Cancer 2Urinary Bladder Neoplasms 1Stage II Prostate Adenocarcinoma 1Salivary Glands Tumors 1Rate of PSA Response in Oligometastatic,CRPC Undergoing SBRT in Combination With Abiraterone Acetate (AA), Compared to Patients Treated With AA Alone 1Prostate Cancer Metastatic 1Prostate Adenocarcinoma 1Pharmacogenetic Study 1Oligometastatic Prostate Carcinoma 1Neoadjuvant Therapy 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Metastatic Hormone Refractory Prostate Cancer 1Metastatic Castration-resistent Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Dementia 1Cushing Syndrome 1Cognitive Dysfunction 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Cancer Pain 1Adrenocortical Carcinoma 1Adenocarcinoma 1

Interventions

abiraterone 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Oligometastatic Prostate Carcinoma × Abiraterone Acetate × Clear all
NCT06369610 2025-11-14

Risk Stratified De-escalated Hormone Therapy With Radiation Therapy for the Treatment of Prostate Cancer

Mayo Clinic

Phase 2 Recruiting
110 enrolled
Genitourinary

Oligometastatic Prostate Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡